Please check your internet connection and try again.
The provided drug name appears to be encoded or contains extraneous characters. Assuming you are requesting information on **Tussionex** (chlorpheniramine and hydrocodone polistirex extended-release suspension), here is the essential drug information.
## Overview
Tussionex is a combination medication containing an opioid antitussive (hydrocodone) and a first-generation antihistamine (chlorpheniramine). It is formulated as an extended-release suspension.
## Primary Indications
* Symptomatic relief of cough.
## Adult Dosing
* **Dose:** 5 mL to 10 mL every 12 hours.
* **Maximum Dose:** Not explicitly defined for continuous use, but typically limited by side effect profile and duration of action. Long-term use is generally not recommended without careful consideration.
## Pediatric Dosing
* **Age 6 to 12 years:** 5 mL every 12 hours.
* **Under 6 years:** Safety and efficacy have not been established. Use is generally not recommended.
## Dose Adjustments
* **Hepatic Impairment:** No specific dosage adjustments are recommended, but caution and closer monitoring are advised due to potential for impaired drug metabolism.
* **Renal Impairment:** No specific dosage adjustments are recommended, but caution and closer monitoring are advised due to potential for impaired drug excretion.
## Contraindications
* Hypersensitivity to hydrocodone, chlorpheniramine, or any component of the formulation.
* Acute asthma or other conditions where bronchospasm may be precipitated.
* Respiratory depression.
* Gastrointestinal obstruction, including paralytic ileus.
* Concurrent use with MAO inhibitors or within 14 days of their discontinuation.
## Adverse Effects
* **Common:** Drowsiness, dizziness, sedation, constipation, nausea, vomiting, dry mouth, blurred vision, urinary retention.
* **Serious:** Respiratory depression, severe sedation, confusion, hypotension, allergic reactions, seizures.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, benzodiazepines, other opioids, sedatives, hypnotics):** Increased risk of profound sedation, respiratory depression, coma, and death.
* **MAO Inhibitors:** May potentiate the effects of hydrocodone and chlorpheniramine, leading to severe CNS depression, hypertensive crisis, or other serious reactions.
* **Anticholinergic Agents:** Increased risk of anticholinergic side effects (e.g., constipation, urinary retention, blurred vision).
## Monitoring
* Assess for effectiveness in cough suppression.
* Monitor for signs of respiratory depression (slowed breathing, shallow breathing, difficulty breathing).
* Monitor for excessive sedation, dizziness, and confusion.
* Monitor for constipation and implement bowel regimen as needed.
* Assess for signs of urinary retention.
## Clinical Pearls
* Due to the extended-release formulation, do not crush, chew, or break the suspension. Shake well before use.
* Tussionex has a potential for misuse, abuse, and diversion. It is a Schedule II controlled substance.
* The antihistamine component can cause significant drowsiness, impairing the ability to drive or operate machinery.
* Consider alternative agents for cough relief, especially in patients with risk factors for respiratory depression or CNS side effects.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and your healthcare provider for diagnosis and treatment. Drug information can change rapidly.
